AroCell: Nomination committee appointed for Annual General Meeting 2017
January 19 2017 - 5:10AM
A decision was taken on May 18,
2016 at the Annual General Meeting for AroCell AB (publ) that a
nomination committee should be appointed and should consist of
three members, comprised of the three largest shareholders on
September 30, 2016, and the Chairman of the Board.
The nomination committee has been appointed
accordingly, based on shareholdings on September 30, 2016:
Bernhard Tribukait, representing his own
shareholdings
Staffan Eriksson, representing his own and related
shareholdings
Jon Eiken, representing his own shareholdings
Erik Walldén, Chairman of the Board
Staffan Eriksson has been appointed as chairman of
the nomination committee.
The nomination committee collectively represents
approximately 10.2 percent of shareholder votes in AroCell AB
(publ).
The Annual General Meeting will be held in
Uppsala, Sweden on May 18, 2017.
Shareholders who wish to contact the nominating
committee may do so by email to info@arocell.com or by letter
to:
Nominating Committee
AroCell AB (publ)
Virdings allé 32B
754 50 UPPSALA
For additional
information:
Jan Stålemark, CEO
AroCell AB (publ)
Tel: +46(0)706926206
info@arocell.com
www.arocell.com
This information is information
that AroCell is obliged to make public pursuant to the EU Market
Abuse Regulation and the Securities Markets Act. The information
was submitted for publication, through Jan Stålemark, at 11:10 CET
on 19 January 2017.
About AroCell
AroCell AB (publ) is a Swedish
company that develops standardized modern blood tests to support
the prognosis and follow up of cancer patients. AroCell's new
technology is based on patented methods to measure TK1 protein
levels, which provide valuable information about the speed of cell
turnover. A tumor has high cell turnover (speed of cell division
and cell death) and as a result TK1 can be detected in the blood
with a simple laboratory test, called TK 210 ELISA. The test
provides valuable clinical information for prognosis and
optimization of treatment strategy. The test may also be used for
monitoring disease relapse. AroCell (AROC) is listed at Nasdaq
First North and has about 2,600 shareholders. For more information,
please see www.arocell.com. Redeye AB is
AroCell:s Certified Adviser.
AroCell press release 170119 Nom
Committe
This
announcement is distributed by Nasdaq Corporate Solutions on behalf
of Nasdaq Corporate Solutions clients.
The issuer of this announcement warrants that they are solely
responsible for the content, accuracy and originality of the
information contained therein.
Source: AroCell AB via Globenewswire
Archrock (NYSE:AROC)
Historical Stock Chart
From Aug 2024 to Sep 2024
Archrock (NYSE:AROC)
Historical Stock Chart
From Sep 2023 to Sep 2024